Literature DB >> 20812021

Natural history of hepatitis B virus infection: pediatric perspective.

Yen-Hsuan Ni1.   

Abstract

Hepatitis B virus (HBV) infection is an important disease globally. Chronic HBV infection may result in serious complications. Its transmission may be either perinatal or horizontal. Perinatal transmission is particularly important after the implementation of a universal vaccination program. Through either route, chronic carrier status is usually established in early childhood. The course of the disease course is determined by the host-virus interaction. The host's immune system initially tolerates the virus, and then gradually attempts to clear it. The virus, on the other hand, tries to avoid host immune system attack by a strategy involving targeted epitope mutations. By generating mutants, the virus can survive attacks from the host's immune system, enabling the infection to persist. Different individuals have different responses to HBV infection; genetic polymorphisms in cytokines, hormones, and other immune modulators may affect the final outcome of chronic HBV infection. Due to the implementation of a universal infant HBV vaccination program, HBV infection is now under control. Unfortunately, there still are some cases of vaccination failure. Very high maternal viremia, in utero infection, or escape mutants are possible reasons for vaccination failure. Immunocompromised hosts also risk vaccination failure. Blood or organ donors with occult HBV infection are possible sources for immunocompromised hosts. These victims of vaccination failure may exhibit a different disease course due to chronic HBV infection from those who acquired the infection before the universal vaccination era. The achievement of our ultimate goal of HBV elimination depends on a globally effective universal vaccination program, as well as the application of some novel successful medications to control those who are already infected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812021     DOI: 10.1007/s00535-010-0304-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  77 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

3.  Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.

Authors:  M W Yu; Y C Yang; S Y Yang; S W Cheng; Y F Liaw; S M Lin; C J Chen
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

4.  Gender disparity of hepatocellular carcinoma: the roles of sex hormones.

Authors:  Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

5.  Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.

Authors:  Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

6.  The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.

Authors:  M H Chang; H Y Hsu; H C Hsu; Y H Ni; J S Chen; D S Chen
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

Review 7.  Rocks along the road to the control of HBV and HCC.

Authors:  R Palmer Beasley
Journal:  Ann Epidemiol       Date:  2009-04       Impact factor: 3.797

8.  RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts.

Authors:  Daw-Jen Tsuei; Hey-Chi Hsu; Po-Huang Lee; Yung-Ming Jeng; Yeong-Shiau Pu; Chiung-Nien Chen; Yung-Chie Lee; Wei-Chun Chou; Chung-Jung Chang; Yen-Hsuan Ni; Mei-Hwei Chang
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

9.  Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  J Med Virol       Date:  2004-03       Impact factor: 2.327

10.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.

Authors:  M van Zonneveld; A B van Nunen; H G M Niesters; R A de Man; S W Schalm; H L A Janssen
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

View more
  22 in total

1.  HLA class II associated with outcomes of hepatitis B and C infections.

Authors:  Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission.

Authors:  Ariane Larouche; Geneviève Gaëtan; Nabil El-Bilali; Mathieu Quesnel-Vallières; Steven R Martin; Fernando Alvarez; Naglaa H Shoukry; Hugo Soudeyns
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

3.  Quasispecies characters of hepatitis B virus in immunoprophylaxis failure infants.

Authors:  Xin Wang; Wanyan Deng; Keli Qian; Haijun Deng; Yong Huang; Zeng Tu; Ailong Huang; Quanxin Long
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-08       Impact factor: 3.267

4.  Chronic hepatitis B in children with or without malignancies: a 13-year follow-up.

Authors:  Merve Usta; Nafiye Urgancı; Zeynep Yıldız Yıldırmak; Sema Dogan Vural
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

5.  A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus.

Authors:  Lei Han; Hong-Wei Zhang; Jia-Xin Xie; Qi Zhang; Hong-Yang Wang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

Review 6.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

7.  Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.

Authors:  Nadine van Montfoort; Evelyn van der Aa; Aniek van den Bosch; Hilde Brouwers; Thomas Vanwolleghem; Harry L A Janssen; Hassan Javanbakht; Sonja I Buschow; Andrea M Woltman
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

8.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

9.  Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study.

Authors:  Mia J Biondi; Alex Marchand-Austin; Kirby Cronin; Natasha Nanwa; Vithusha Ravirajan; Erin Mandel; Lee W Goneau; Tony Mazzulli; Hemant Shah; Camelia Capraru; Harry L A Janssen; Beate Sander; Jordan J Feld
Journal:  CMAJ       Date:  2020-10-26       Impact factor: 8.262

10.  The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions.

Authors:  Jördis J Ott; Gretchen A Stevens; Steven T Wiersma
Journal:  BMC Infect Dis       Date:  2012-06-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.